Business Context and Reporting Period
Company: ImmuCell Corporation
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 1996
Business Overview: ImmuCell is a biotechnology company focused on developing passive antibody products to prevent gastrointestinal infections, including cryptosporidiosis and traveler's diarrhea. The company relies on product sales, collaborative research revenue, and federal grants to fund operations.
Key Financial Metrics
| Metric | Q1 1996 | Q1 1995 |
|---|---|---|
| Total Revenues | $1,416,011 | $1,475,186 |
| Net (Loss) Profit | $(11,678) | $102,394 |
| Net Cash Used in Operating Activities | $(216,623) | $138,975 |
| Cash and Cash Equivalents (Ending) | $1,143,309 | $945,196 |
| Total Assets | $3,082,333 | $3,234,426 |
| Total Liabilities | $1,188,695 | $1,329,110 |
| Stockholders' Equity | $1,893,638 | $1,905,316 |
| Product Gross Margin | 57% | 55% |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by approximately 4% ($59,000) compared to Q1 1995. Product sales dropped 7% ($95,000), primarily driven by a 9% decline in sales of the company's two flagship products, FIRST DEFENSE and the KAMAR HEATMOUNT DETECTOR.
- Profitability Shift: The company reported a net loss of $11,678 in Q1 1996, reversing a net profit of $102,394 in the same period of 1995.
- Expense Increases: Research and development (R&D) expenses surged 34% to $501,058, driven by significant clinical trial costs not present in the prior year. General and administrative expenses rose 18% to $179,796.
- Cash Flow Deterioration: Operating cash flow turned negative, using $216,623, compared to a positive $138,975 in Q1 1995. This was largely due to increases in accounts receivable and decreases in accounts payable.
- Liquidity: Cash and cash equivalents decreased by approximately $407,000 during the quarter to $1.14 million. Net working capital declined by $178,000.
Guidance, Outlook, and Risks
- Outlook: Management expects to incur further operating losses as it aggressively invests in R&D to demonstrate efficacy in Phase I/II clinical trials. The strategy involves pursuing corporate partners to fund continued development in exchange for marketing rights.
- Grant Funding: The company holds approximately $188,000 in remaining grant funds from NIAID SBIR grants as of March 31, 1996, designated for internal R&D and outside laboratory services.
- Capital Resources: Management believes current capital resources are sufficient to meet working capital requirements and finance operations for the next twelve months.
- Strategic Partnership: On March 25, 1996, ImmuCell entered a license agreement with CSI Clinical Trials, Inc. to conduct clinical testing for BACI (bovine anti-cryptosporidium immunoglobulins). ImmuCell will pay CSI a royalty on net sales of BACI.
- Risks: The company faces risks related to the success of clinical trials, FDA approval (specifically regarding orphan drug law exclusivity), and the ability to secure future funding or corporate partnerships to sustain R&D.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $1.14 million cash balance given the negative operating cash flow of $216k in a single quarter.
- Grant Expiration: Confirm the timeline for the remaining $188,000 in grant funds and the status of the NIAID SBIR grants extended through October 1996.
- Clinical Trial Progress: Assess the status of the Phase I/II trials for cryptosporidiosis and traveler's diarrhea, as future funding depends on demonstrating efficacy.
- Debt Obligations: Review the $736,756 in total debt obligations, noting the current portion of $176,634 and the scheduled principal payments due in 1996 ($129,000).
- Product Concentration: Note that 84% of product sales rely on two specific products (FIRST DEFENSE and KAMAR HEATMOUNT DETECTOR), which are currently experiencing sales declines.